BACKGROUND: Most systemic lupus erythematosus (SLE) patients with two or more clinical manifestations of the antiphospholipid syndrome (APS) and negative antiphospholipid antibodies (aPL) have antibodies to beta 2-glycoprotein-I (a beta 2 GP-I). Herein we describe a similar set of circumstances, but in patients without evidence of SLE. PATIENTS AND METHODS: We studied 6 patients with recurrent venous and/or arterial thromboses without aPL as detected by routine assays nor clinical or serological evidence of other autoimmune disease. Immunoglobin (Ig) G and IgM antibodies to bovine and human phospholipid-free beta 2 GP-I were studied by Western blot test and by enzyme-linked immunosorbent assay (ELISA) utilizing radiated and nonirradiated plates. We also tested antibodies to cardiolipin, phosphatidylserine, and phosphatidylethanolamine by ELISA. As controls, 54 normal sera were studied. RESULTS: All 6 patients had recurrent arterial and/or venous thromboses. Three also had thrombocytopenia, 1 had livedo reticularis, and 2 had valvular heart disease. None of the patients had aPL, but all had serum IgG reactivity against human and bovine beta 2 GP-I (P < 0.001 versus controls for both). Titers of anti-bovine beta 2 GP-I were higher when studied in irradiated plates but were also higher than normal in nonirradiated plates (P < 0.001). These antibodies did not recognize human or bovine beta 2 GP-I bound to cardiolipin in solid phase. We confirmed by Western blot that these autoantibodies recognize human beta 2 GP-I. We found no IgM a beta 2 GP-I. CONCLUSIONS: We describe a primary condition akin to the antiphospholipid syndrome with negative aPL, but with serum IgG antibodies to human and bovine beta 2 GP-I. These antibodies recognize beta 2 GP-I epitopes that are not accessible when beta 2 GP-I is bound to cardiolipin.
BACKGROUND: Most systemic lupus erythematosus (SLE) patients with two or more clinical manifestations of the antiphospholipid syndrome (APS) and negative antiphospholipid antibodies (aPL) have antibodies to beta 2-glycoprotein-I (a beta 2 GP-I). Herein we describe a similar set of circumstances, but in patients without evidence of SLE. PATIENTS AND METHODS: We studied 6 patients with recurrent venous and/or arterial thromboses without aPL as detected by routine assays nor clinical or serological evidence of other autoimmune disease. Immunoglobin (Ig) G and IgM antibodies to bovine and humanphospholipid-free beta 2 GP-I were studied by Western blot test and by enzyme-linked immunosorbent assay (ELISA) utilizing radiated and nonirradiated plates. We also tested antibodies to cardiolipin, phosphatidylserine, and phosphatidylethanolamine by ELISA. As controls, 54 normal sera were studied. RESULTS: All 6 patients had recurrent arterial and/or venous thromboses. Three also had thrombocytopenia, 1 had livedo reticularis, and 2 had valvular heart disease. None of the patients had aPL, but all had serum IgG reactivity against human and bovinebeta 2 GP-I (P < 0.001 versus controls for both). Titers of anti-bovinebeta 2 GP-I were higher when studied in irradiated plates but were also higher than normal in nonirradiated plates (P < 0.001). These antibodies did not recognize human or bovinebeta 2 GP-I bound to cardiolipin in solid phase. We confirmed by Western blot that these autoantibodies recognize humanbeta 2 GP-I. We found no IgM a beta 2 GP-I. CONCLUSIONS: We describe a primary condition akin to the antiphospholipid syndrome with negative aPL, but with serum IgG antibodies to human and bovinebeta 2 GP-I. These antibodies recognize beta 2 GP-I epitopes that are not accessible when beta 2 GP-I is bound to cardiolipin.
Authors: M L Bertolaccini; S Gomez; J F P Pareja; A Theodoridou; G Sanna; G R V Hughes; M A Khamashta Journal: Ann Rheum Dis Date: 2005-04-07 Impact factor: 19.103
Authors: B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; G Palladini; G Valesini Journal: Clin Exp Immunol Date: 1999-01 Impact factor: 4.330
Authors: Colum F Amory; Steven R Levine; Robin L Brey; Mulugeta Gebregziabher; Stanley Tuhrim; Barbara C Tilley; Ann-Catherin C Simpson; Ralph L Sacco; Jay P Mohr Journal: Cerebrovasc Dis Date: 2015-10-29 Impact factor: 2.762
Authors: Kamil Bugała; Adam Mazurek; Krzysztof Gryga; Monika Komar; Grzegorz Kopeć; Jacek Musiał; Piotr Podolec; Carlo Perricone; Wojciech Płazak Journal: Clin Rheumatol Date: 2018-04-20 Impact factor: 2.980
Authors: Sherry D Fleming; Michael R Pope; Sara M Hoffman; Tiffany Moses; Urska Bukovnik; John M Tomich; Lynn M Wagner; Keith M Woods Journal: J Immunol Date: 2010-10-18 Impact factor: 5.422